Inspire Medical Q2 2026: Revenue Hits $200.6M, Guidance Raised, $30M Reinvestment Strategy Unveiled

What happened

Inspire Medical Systems reported second-quarter 2026 revenue of $200.6 million, with diluted EPS of $0.01 and adjusted diluted EPS of $0.14, alongside operating cash flow of $23.2 million. The company raised its full-year 2026 guidance and announced a strategic growth plan that unlocks and redeploys $30 million for growth initiatives, signaling a focus on operational efficiency and reinvestment. CEO Tim Herbert credited increased discipline and focus, noting that the team continues to support customers through an evolving coding and reimbursement environment while investing in long-term adoption of Inspire therapy. The results reflect a stabilization of the business after a turbulent 2025, driven by the ongoing Inspire V rollout and early benefits from the Medicare facility-fee uplift. However, the quarter’s performance must be weighed against persistent GLP-1 competitive headwinds and the unresolved DOJ civil investigative demand that could constrain future commercial flexibility.

Implication

The Q2 2026 beat and guidance raise confirm that Inspire is executing well despite GLP-1 competition, supporting the base case for 13%+ revenue growth and margin improvement in 2026. The $30 million strategic redeployment plan signals management’s discipline in freeing up capital for high-return growth initiatives, which should support operating leverage and EPS acceleration. However, the market still must assess whether the raised guidance factors in potential second-half GLP-1 volume displacement or any payer pushback following the reimbursement increase. Near-term, the results and outlook shift the risk-reward modestly in favor of the bull case, but the stock’s P/E remains elevated at ~55x trailing EPS, leaving little room for execution missteps. Investors should watch for confirmation that primary care referrals are converting to Inspire implants at a rate sufficient to sustain double-digit procedure growth in the face of expanding Zepbound OSA prescribing.

Thesis delta

The Q2 2026 beat and raised guidance strengthen the base-case thesis that Inspire can compound revenue at 10–13% annually with margin expansion as Inspire V adoption and Medicare reimbursement gains mature. The $30 million cost-reinvestment plan directly addresses prior concerns about expense bloat and shows management is proactively shifting capital to growth, which could lift normalized EPS toward $2+ by late 2026. While GLP-1 and DOJ risks remain, this quarter suggests execution is improving and the derated valuation may not fully reflect the earnings power now emerging.